Private Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Private Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,000	Closed	-$811K	–	97
2018 Q1	$811K	Buy	+10,000	New	+$858K	0.27%	56
2017 Q1	–	Sell	-4,000	Closed	-$331K	–	119
2016 Q4	$331K	Buy	+4,000	New	+$344K	0.11%	100
2015 Q3	–	Sell	-4,700	Closed	-$643K	–	114
2015 Q2	$643K	Buy	+4,700	New	+$582K	0.21%	91
2013 Q4	–	Sell	-90,514	Closed	-$6.53M	–	107
2013 Q3	$6.53M	Sell	90,514 -30,836	-25%	-$2.05M	2.37%	4
2013 Q2	$6.76M	Buy	+121,350	New	+$7.56M	2.51%	3

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Private Capital Advisors's BMRN Position: Q2 2018 in Review

Private Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 10,000 shares — an estimated $811K sold.

Private Capital Advisors first reported a position in BMRN in Q2 2013 and held it in 5 quarters. The position peaked at $6.76M in Q2 2013. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Private Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Private Capital Advisors sold 10,000 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $811K.
Private Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Private Capital Advisors's BioMarin Pharmaceuticals position peaked at $6.76M in Q2 2013.
449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Private Capital Advisors's 13F filing for Q2 2018, filed 10 Jul 2018.